Topic

Articles

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.










Broadening the Scope of Small Molecules: Ventus Therapeutics

With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.

Tuning and Tracking CAR-T Cells for Safer and More Effective Treatment for Solid Tumors 

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

How Gilead readied remdesivir for the COVID challenge.

Betting on Its Base in Virology

Inside Regeneron’s monoclonal antibody development to treat COVID.

Scientific Rigor, Urgent Action

Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.

Meeting the Crisis Head-On

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mjhlifesciences.com

Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.

Innovation in High Gear

College roommates, industry partnerships help bring Pfizer vaccine to fruition.

Bonds Old and New to the Rescue

Brent Vaughan is CEO, Cognito Therapeutics.

The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.

Moving Beyond Traditional Approaches to Alzheimer’s Disease 

Marco Quarta is CEO of Rubedo Life Sciences.

The field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.

The Rise of Longevity Therapeutics

Annovis Bio's Maria L. Maccecchini, Ph.D., talks about why she, as a scientist and biotech company entrepreneur, became focused on protecting nerve cells in the brain and in the body, as a way to treat neurodegenerative disease.





R&D/Clinical Trials